No description available.

Tübingen, Univ., Diss., 2008.

Zugl.: Hamburg, Univ., Diss., 2009

Techn. University, Diss., 2003--München.

Universiẗat, Diss., 2003--Kiel.

<p>Kingella kingae is a bacterial pathogen that is increasingly recognized as an etiology of septic arthritis, osteomyelitis, bacteremia, and endocarditis in young children. The pathogenesis of K. kingae disease starts with bacterial adherence to the respiratory epithelium of the posterior pharynx. Previous work has identified type IV pili and a trimeric autotransporter protein called Knh (Kingella NhhA homolog) as critical factors for adherence to human epithelial cells. Additional studies established that the presence of a polysaccharide capsule interferes with Knh-mediated adherence. Given the inhibitory role of capsule during adherence we sought to uncover the genes involved in capsule expression to understand how capsule is elaborated on the cell surface. Additionally, this work aimed to further characterize capsule diversity among K. kingae clinical isolates and to investigate the relationship between capsule type and site of isolation. </p><p>We first set out to identify the carbohydrates present in the K. kingae capsule present in the prototype strain 269-492. Glycosyl composition and NMR analysis of surface extractable polysaccharides demonstrated two distinct polysaccharides, one consisting of GalNAc and Kdo with the structure →3)-β-GalpNAc-(1→5)-β-Kdop-(2→ and the other containing galactose alone with the structure →5)-β-Galf-(1→. </p><p>To discern the two polysaccharides we disrupted the ctrA gene required for surface localization of the K. kingae polysaccharide capsule and observed a loss of GalNAc and Kdo but no effect on the presence of Gal in bacterial surface extracts. In contrast, deletion of the pamABCDE locus involved in production of a reported galactan exopolysaccharide eliminated Gal but had no effect on the presence of GalNAc and Kdo in surface extracts. These results established that K. kingae strain KK01 produces a polysaccharide capsule with the structure →3)-β-GalpNAc-(1→5)-β-Kdop-(2→ and a separate exopolysaccharide with the structure →5)-β-Galf-(1→. </p><p>Having established that K. kingae produces a capsule comprised of GalNAc and Kdo, we next set out to identify the genetic determinants of capsule through a transposon mutagenesis screen. In addition to the previously identified ctrABCD operon, lipA, lipB, and a putative glycosyltransferase termed csaA (capsule synthesis region A gene A) were found to be essential for the production of surface-localized capsule. The ctr operon, lipA, lipB, and csaA were found to be present at unlinked locations throughout the genome, which is atypical for gram-negative organisms that elaborate a capsule dependent on an ABC-type transporter for surface localization. Through examining capsule localization in the ctrA, lipA, lipB, and csaA mutant strains, we determined that the ctrABCD, lipA/lipB, and csaA gene products respectively function in capsule export, assembly, and synthesis, respectively. The GalNAc transferase and Kdo transferase domains found in CsaA further support its role in catalyzing the synthesis of the GalNAc-Kdo capsule in the K. kingae prototype strain.</p><p>To investigate the capsule diversity that exists in K. kingae we screened a panel of strains isolated from patients with invasive disease or healthy carriers for the csaA capsule synthesis locus. We discovered that Kingella kingae expresses one of 4 capsule synthesis loci (csa, csb, csc, or csd) associated with a capsule consisting of Kdo and GalNAc (type a), Kdo and GlcNAc (type b), Kdo and ribose (type c), and GlcNAc and galactose (type d), respectively. Cloning of the csa, csb, csc, or csd locus into the empty flanking gene region in a non-encapsulated mutant (creation of an isogenic capsule swap) was sufficient to produce either the type a, type b, or type c capsule, respectively, further supporting the role of these loci in expression of a specific polysaccharide linkage. Capsule type a and capsule type b accounted for 96% of invasive strains. Conversely, capsule type c and capsule type d were found disproportionately among carrier isolates, suggesting that capsule type is important in promoting invasion and dissemination. </p><p>In conclusion, we discovered that Kingella kingae expresses a polysaccharide capsule and an exopolysaccharide on its surface that require distinct genetic loci for surface localization. Further investigation into genetic determinants of encapsulation revealed the loci ctrABCD, lipA/lipB, and a putative glycosyltransferase are required for capsule expression, with the gene products having roles in capsule export, assembly, and synthesis, respectively. The putative glycosyltransferase CsaA was determined to be a bifunctional enzyme with both GalNAc-transferase and Kdo-transferase activity. Furthermore, we discovered a total of 4 capsule types expressed in clinical isolates of K. kingae, each with a distinct capsule synthesis locus. The variation in the proportion of capsule types found between invasive strains and carriage strains suggest that capsule type is important in promoting invasion and dissemination. Taken together, this work expands our knowledge of the capsule types expressed among K. kingae carrier and invasive isolates and provides insights into the common genetic determinants of capsule expression. These contributions may lead to selecting clinically relevant capsule types to develop into a capsule based vaccine to prevent K. kingae colonization.</p> / Dissertation

La prise en charge du diabète de type I se fait à l’heure actuelle par des injections pluriquotidiennes d’insuline ou par l’utilisation d’une pompe à insuline qui va mimer l’activité pancréatique. Dans ce contexte, les nanogels sensibles au glucose représentent des candidats à fort potentiel pour une délivrance contrôlée de l’insuline.La majorité des matériaux développés à ce jour ne présentent pas d’études en vue d’application in vivo et ce, pour diverses raisons telles que la non validation du caractère biocompatible et biorésorbable de la matrice polymère. Afin de répondre à ces deux critères, nous avons choisi de développer des nanogels à base de polysaccharides biocompatibles et biodégradables.Des travaux antérieurs au sein du laboratoire ont porté sur la conception d’hydrogels à base d’acide hyaluronique. Le polysaccharide a été fonctionnalisé avec des dérivés de l’acide phénylboronique (PBA) et du maltose. Ces modifications permettent dans des conditions physiologiques de générer des réticulations boronate-ester. Ces liaisons permettent d’induire une modification de la structure des hydrogels en réponse à divers stimuli tel que le pH ou l’addition de composés saccharidiques.Afin de faciliter l’administration de tels matériaux, nous avons étendu ce concept à la formation de nanogels. Des nanogels sensibles au pH et/ou à l’addition de saccharides ont pu être obtenus en conditions physiologiques grâce au choix judicieux des polysaccharides partenaires modifiés par le PBA et des molécules portant des fonctions diol. Ces nanogels sont capables de piéger l’insuline lors de leur formation avec une efficacité d’encapsulation allant de 45% à 80% et une capacité d’encapsulation de 10% à 60%. Les premiers tests ont montré un faible relargage de l’insulin par nos nanogels.Finalement, au vue de la sensibilité au pH de nos nanogels et l’environnement acide présent autour des tumeurs, leur utilisation pour le traitement du cancer a été étudié. Des analyses in vitro ont démontré une faible toxicité de nos gels sur les cellules cancéreuses. Les premières expériences in vivo ont montré la capacité des nanogels à circuler dans le sang. / Type 1 diabetes management is currently done by multiple insulin injections or by the use of an insulin pump that will mimic pancreatic activity. In this context, glucose-sensitive nanogels represent high potential candidates for controlled delivery of insulin.The majority of materials developed so far are limited to biological in vitro studies, which is partly due to the non-biocompatibility and limited biodegradability of polymers used for the preparation of such materials. To fulfill these criteria, we proposed to develop nanogels based on biocompatible and biodegradable polysaccharides.Previous work in our laboratory focused on the design of boronate-crosslinked hydrogels based on hyaluronic acid. This polysaccharide was functionalized with derivatives of phenylboronic acid (PBA) and of maltose. The dynamic covalent boronate ester crosslinks between the polysaccharide chains enabled to induce a structural change of the hydrogel in response to various stimuli such as pH or addition of carbohydrate molecules.In order to facilitate administration of such materials, we extended the concept to the formation of nanogels. Sugar- and pH-sensitive nanogels could be successfully obtained in physiological conditions thanks to the judicious choice of the polysaccharide partners, bearing PBA moieties and diol-containing molecules.These nanogels can entrap insulin during their formation with an entrapment efficiency of 45% to 80% and a loading capacity ranging from 10% to 60%. Preliminary experiments indicated a low release of insulin from the nanogels.Finally, in view of the pH-sensitivity of these nanogels and the slight acidic pH of the tumor environment, we investigated their potential application for the treatment of cancer. In vitro experiment demonstrated a low toxicity of our nanogels on cancer cells. Preliminary in vivo experiments indicated that the nanogels can circulate in the bloodstream.

Salmonella infections remain one of the most common food borne diseases worldwide. Gastroenteritis, which can be caused by many non-typhoidal Salmonella (NTS) serovars, is relatively common in North America. One of the main risk factors of NTS gastroenteritis is travel to endemic areas in the developing world. The current treatment of NTS infections with antibiotics is reserved for severe cases. A growing concern with antibiotic use is that clinical isolates are becoming drug resistant. Although most NTS infections are self-limiting in nature, the burden on the body and recovery can take several months. Thus, it is vital to prevent NTS infections rather than solely rely on treatment. We have previously discovered two novel surface associated polysaccharides in Salmonella: O-Antigen capsule and X-factor. Not only O-Antigen Capsule is considered a common surface antigen, but its’ genes were found to be expressed during in vivo infections in mice. Such an antigen would be a suitable candidate in developing a vaccine against Salmonella induced gastroenteritis. The goal of this research was to evaluate the use of O-Antigen capsule to develop a traveler’s vaccine for NTS associated gastroenteritis. Results and Conclusions: We have developed a purification protocol and purified the capsule and X-factor from Salmonella Typhimurium, Enteritidis, and Heidelberg. Lipopolysaccharide (LPS) was co-isolated with O-Antigen capsule, but removed using Triton extraction. Salmonella LPS is strain-specific and an adaptive immune response against LPS will not provide cross-protection. We generated specific immune sera in rabbits to recognize O-Antigen capsule and X-factor produced by Salmonella Typhimurium and Enteritidis. We used a mouse model to determine the immunization dose of O-Antigen capsule and showed that conjugation is necessary to enhance the immune response in mice. To boost capsule production, we analyzed PyihUTSRQPO activity using a luciferase-based reporter system. Deletion of a putative transcriptional repressor (YihW) resulted in over 100-fold increase in PyihUTSRQPO confirming YihW as a repressor. We have also looked at the effect of growth media, temperature, and sugar precursors on PyihUTSRQPO activity, and were able to show that PyihUTSRQPO has highest activity in Tryptone broth at 30oC in the absence of any additional sugars.

Astragalus gombo Bunge (Fabaceae) est une plante bien représentée dans le Sahara Septentrional Est Algérien (région de Ouargla, Algérie) et couramment utilisée comme fourrage pour les animaux ou en médecine traditionnelle. Malgré de nombreuses publications sur la richesse en polysaccharides d’autres espèces appartenant au genre Astragalus et la description de leurs propriétés biologiques putatives ou avérées, aucune étude ne s’est intéressée à l’espèce gombo. L’objectif de ce travail de thèse a donc été de réaliser des investigations sur plusieurs parties de cette plante en vue d’extraire, identifier et caractériser son contenu en polysaccharides. Dans un second temps les propriétés biologiques et rhéologiques de ces polymères ont été étudiées afin d’identifier d’éventuelles voies de valorisation. Les résultats obtenus ont permis de détecter la présence de composés pectiques et hémicellulosiques dans la tige d’Astragalus gombo et celle d’un galactomannane dans les graines. Le galactomannane est de haute masse moléculaire (1,1x106 Da) et est constitué d’une chaine principale de β-(1→4)-D-mannane ramifiée en α-(1→6) par des résidus Dgalactopyranoses avec un rapport M/G de 1,7. La caractérisation de ses propriétés rhéologiques a révélé un comportement typique rhéofluidifiant et des propriétés viscoélastiques. L’étude des activités biologiques associées à ce biopolymère a révélé son potentiel comme prébiotique et antioxydant. / Astragalus gombo Bunge (Fabaceae) is a terrestrial plant occuring in the East Septentrional Sahara (Ouargla, Algeria). It is commonly used as fodder or in traditional medicine by local populations. Despite numerous publications focusing on polysaccharidic contents of Astragalus species and the designation of their putative or proved biological activities, no study has examined those of A. gombo. The objective of this thesis was firstly to investigate several organs of this plant for their polysaccharide contents. In a second step, the biological and rheological properties of these biopolymers have been studied to identify ways of adding value. Results led to the identification of pectic compounds and hemicelluloses in the rods of Astragalus gombo whereas a galactomannan was detected in its seeds. This galactomannan was a high molecular weight macromolecule composed of a β-(1→4)-D-mannan skeleton ramified by residues of D-galactopyranoses. The M/G ratio was of 1.7. The characterization of its rheological behavior was typic of that of a rheofluidifiant fluid with viscoelastic properties. The study of its biological properties showed its potential as prebiotic and antioxidant agent.

Synthetic strategies for polysaccharide-protein conjugates, pH-responsive hydrogels, and amorphous solid dispersion (ASD) polymers were developed. Conjugating a polysaccharide to a protein drug via a covalent bond may improve its medical properties including solubility, stability, immunogenicity, circulation time, and targeting ability. Regioselectivity of conjugation is still challenging. We developed a strategy for regioselective conjugation of amino acid esters to polysaccharides, by employing 6-Br-polysaccharides in SN2 substitution reactions with amino acid esters. This work provides a good starting point for the regioselective conjugation of polysaccharides to proteins. Polysaccharides can also serve as hydrogel drug carriers. Most hydrogels employed in drug delivery work by incorporating the drug physically. We synthesized sustained and pH-responsive hydrogels using oxidized hydroxypropyl cellulose (Ox-HPC)/carboxymethyl chitosan (CMCS) crosslinked by imine bond. Phenylalanine as a model amine-containing drug was chemically bonded to the Ox-HPC hydrogel component and was observed to release faster at the pH of a tumor microenvironment. These hydrogels show promise as targeting cancer drug carriers. ASDs are polymeric systems to disperse poorly soluble drugs amorphously and enhance permeation from the gastrointestinal tract (GI tract) to the bloodstream. We synthesized potentially zwitterionic cellulose derivatives by reductive amination of Ox-HPC with ω-aminoalkanoic acids and obtained products with the degree of substitution (cation and anion) up to 1.6, which is difficult to attain using previous methods. The products showed manipulated amphiphilicity and excellent thermostability, exhibiting potential application in ASDs. We anticipate that these strategies will benefit future polysaccharide chemistry research and permit synthesis of a broad variety of more functional biomedical materials. / Doctor of Philosophy / Polysaccharides are long chains of individual sugars ("polymers"). Many natural-sourced polysaccharides are sustainable, biodegradable, and have low toxicity. Polysaccharide-based materials may improve the properties of current drugs, resulting in decreased cost, enhanced absorption efficiency, and continuous and/or targeted delivery. Protein drugs such as human insulin have a significant role in medicine. However, the residence time of a protein drug in the human body is short. To overcome this challenge, we designed a method to link polysaccharides to proteins at controlled reaction sites, and reported herein the first step of this route. The final polysaccharide-protein products will even have the ability to recognize and access target cells, like those of tumors. Tumor tissues are more acidic than normal tissue and can trigger faster release of drug from drug carriers. We developed polysaccharide-based hydrogels, which are gels that bind a great deal of water but won't dissolve in it, as acid-sensitive carriers. In addition, our hydrogels are also injectable, and can spontaneously repair themselves. These properties make our hydrogels promising as cancer targeting drug carriers. Most new drug candidates have poor water solubility and permeation through the gastrointestinal tract to reach the blood stream. Dispersing the insoluble drug into a properly designed polymer network can enhance dissolution, permeation, and absorption. We developed a new family of polymers designed for this purpose using two cheap starting materials. These polymers can interact with the drug, preventing it from forming crystals and simultaneously promoting slow drug release. Overall, we explored ways to modify polysaccharides to create harmless, effective medical materials. We aim to promote science and benefit human health via our research.